Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Impact · against what's priced in

The Phase 3 success of epcoritamab in frontline DLBCL is a positive catalyst for both companies, as it expands the addressable market into a new patient population. For AbbVie, this specifically validates an oncology pipeline that the market has previously ignored in its valuation.

ABBV+0.60

Challenges what's priced in

The price assumes